Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The parties will collaborate to conduct a Phase II clinical trial to evaluate the combination of an experimental ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Merck, a leading science and technology company, today launched a beta version of M-Trust™, a secure cyber-physical trust ...

BusinessWire India Accra [Ghana]Mumbai Maharashtra [India] January 9 Merck Foundation the philanthropic arm of Merck KGaA ...